NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

NCT03289182

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: MabThera

Countries: South Korea

This is a prospective, multicenter, non-interventional study to test the safety and effectiveness of MabThera administered subcutaneously in participants with NHL or CLL. The length of study is expected to be 6 years.

Eligibility overview

Sex: ALL

Age: 19 Years to

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Participants administered with MabThera subcutaneously within the approved indication in Korea
* Participants previously untreated with MabThera subcutaneously

Inclusion Criteria for NHL participants for MabThera subcutaneously 1400mg:

* Relapsed or chemoresistant follicular lymphoma (FL) (B, C, and D type by international working formulation classification of B-cell NHL) participants
* Previously untreated FL participants in combination with chemotherapy
* Participants who are treated with maintenance therapy after the treatment of FL participants responding to induction therapy.
* Cluster of differentiation 20-positive, diffuse large B-cell NHL participants in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (8 cycles) chemotherapy

Inclusion Criteria for CLL participants for MabThera subcutaneously 1600mg:

\- Previously untreated or relapsed/refractory CLL participants in combination with chemotherapy

Exclusion Criteria:

* Pregnant or breastfeeding women
* Participants who are out of locally approved indications, dosage, and administration including medication error
* Contraindication in use by locally approved indications, dosage, and administration
Locations (25)
  • Bucheon-si, South Korea
  • Busan, South Korea
  • Busan, South Korea
  • Daegu, South Korea
  • Daegu, South Korea
  • Daegu, South Korea
  • Daejeon, South Korea
  • Gyeonggi-do, South Korea
  • Gyeonggi-do, South Korea
  • Gyeonggi-do, South Korea
  • Gyeongsangnam-do, South Korea
  • Incheon, South Korea
  • Jeollanam-do, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Ulsan, South Korea